TACR3
ENSG00000169836
Target class
GPCR
Chromosome
4
Approved drugs
1
Clinical candidates (approved and in development)
4
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Target name
- TACR3
- Gene name
- Tachykinin receptor 3
- Gene symbol
- TACR3
- Protein name
- Neuromedin-K receptor (NKR) (NK-3 receptor) (NK-3R) (Neurokinin B receptor) (Tachykinin receptor 3)
- NK3R
- NKR
- TAC3R
- Gene biotype
- Protein coding
- Gene family
- Tachykinin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 2
- Highest tissue expression
- 1.34
- Tissue specificity (Gini)
- 0.838
- Tissue specificity (tau)
- 0.943
- KEGG gene identifiers
- hsa:6870
- Protein interaction confidence
- 0.836
- Protein interaction partners
- 11
- R-HSA-380095
- R-HSA-416476
- End position
- 103719985
- Start position
- 103586031
- Chromosome
- 4
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
Publication evidence
- PubMed 37968728
- Tissue specificity (tau)
- 0.942551
- Expression inequality (Gini)
- 0.838048
Expression in transcripts per million
- Brain - Hypothalamus
- 1.34
- Bladder
- 1.16
- Brain - Spinal cord (cervical c-1)
- 0.51
- Brain - Substantia nigra
- 0.42
- Brain - Amygdala
- 0.38
Expression in transcripts per million
- Brain - Hypothalamus1.34
- Bladder1.16
- Brain - Spinal cord (cervical c-1)0.51
- Brain - Substantia nigra0.42
- Brain - Amygdala0.38
- Brain - Hippocampus0.25
- Brain - Frontal Cortex (BA9)0.16
- Kidney - Cortex0.16
- Brain - Anterior cingulate cortex (BA24)0.16
- Brain - Nucleus accumbens (basal ganglia)0.14
- Brain - Cortex0.14
- Brain - Putamen (basal ganglia)0.12
- Brain - Caudate (basal ganglia)0.11
- Testis0.08
- Pituitary0.06
- Lung0.05
- Muscle - Skeletal0.03
- Kidney - Medulla0.03
- Brain - Cerebellar Hemisphere0.02
- Thyroid0.02
- Brain - Cerebellum0.02
- Skin - Sun Exposed (Lower leg)0.02
- Stomach0.01
- Colon - Transverse0.01
- Small Intestine - Terminal Ileum0.01
And 29 more, listed on the interactive page.
- GO:0007209
- GO:0007217
- GO:1902093
- GO:0005886
- GO:0097225
- GO:0004995
- GO:0005515
- GO:0016498
Contraction of gastric smooth muscle and ileum
Effects
- Activation/Increase/Upregulation
Studies
- preclinical
Biological samples
- GI
PubMed 38773351
Related records
Trials (87)
- A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
- A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
- A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression
- A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
- A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain
- A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
- A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice
- A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause
- A Study of AZD4901 in Females With Polycystic Ovary Syndrome
- A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms
- A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
- A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants
- A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause
- A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants
- A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
Drugs (9)
- Eledoisin
- Elinzanetant Neurokinin 3 receptor antagonist
- Fezolinetant Neurokinin 3 receptor antagonist
- Osanetant
- Pavinetant Neurokinin 3 receptor antagonist
- Saredutant
- Substance P
- Talnetant Neurokinin 3 receptor antagonist
- Talnetant hydrochloride Neurokinin 3 receptor antagonist